ViaCyte Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 111

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $320M

ViaCyte General Information

Description

Developer of novel cell replacement therapies and regenerative medicine intended to address critical human diseases and disorders. The company's therapies are based on two major technological advances including cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation, enabling healthcare institutions to reduce the risk of hypoglycemia and diabetes-related complications.

Contact Information

Website
www.viacyte.com
Formerly Known As
Novocell, CyThera
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 5580 Morehouse Drive
  • Suite 100
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 5580 Morehouse Drive
  • Suite 100
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ViaCyte Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
26. Merger/Acquisition 27-Sep-2022 $320M Completed Clinical Trials - Phase 2
25. Later Stage VC (Series D) 09-Jun-2021 Completed Clinical Trials - Phase 2
24. Secondary Transaction - Private Completed Clinical Trials - General
23. Later Stage VC (Series D2) 26-May-2020 Completed Clinical Trials - General
22. Later Stage VC 25-Sep-2018 Completed Clinical Trials - General
21. Grant 17-Apr-2018 Completed Clinical Trials - General
20. Grant 15-Dec-2017 Completed Clinical Trials - General
19. Later Stage VC 22-May-2017 Completed Clinical Trials - General
18. Grant 01-Jan-2017 $23.1M $104M Completed Clinical Trials - General
17. Grant 11-Sep-2014 $16.6M $104M Completed Clinical Trials - General
To view ViaCyte’s complete valuation and funding history, request access »

ViaCyte Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D-4A
Series D-4
Series D-3A
Series D-3
Series D1
Series C1
Series C
Series B 27,876,992 $0.001000 8% $1 $1 1x $1 3.89%
Series A 8,020,005 $0.001000 8% $1 $1 1x $1 1.12%
To view ViaCyte’s complete cap table history, request access »

ViaCyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel cell replacement therapies and regenerative medicine intended to address critical human diseases and
Drug Discovery
San Diego, CA
111 As of 2022

Madison, WI

Stockholm, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ViaCyte Competitors (19)

One of ViaCyte’s 19 competitors is Regenerative Medical Solutions, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenerative Medical Solutions Venture Capital-Backed Madison, WI
Diamyd Medical Corporation Stockholm, Sweden
BioCardia Formerly VC-backed Sunnyvale, CA
Sernova Biotherapeutics Corporation Mississauga, Canada
Orgenesis Corporation Germantown, MD
You’re viewing 5 of 19 competitors. Get the full list »

ViaCyte Patents

ViaCyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250090596-A1 Modulating inflammation associated with foreign body response Pending 14-Sep-2023
US-20240249308-A1 Information processing device, and information processing method Inactive 25-Jan-2023
EP-4593761-A2 Anchor regions for implantable medical device Pending 30-Sep-2022
US-20250269161-A1 Anchor regions for implantable medical device Pending 30-Sep-2022
WO-2024073736-A2 Anchor regions for implantable medical device Inactive 30-Sep-2022 A61F2/022
To view ViaCyte’s complete patent history, request access »

ViaCyte Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ViaCyte Former Investors (34)

Investor Name Investor Type Holding Investor Since Participating Rounds
AMA98 ventures Limited Partner Minority
ARTIS (San Francisco) Venture Capital Minority
ATEL Capital Group Asset Manager Minority
Adage Capital Management Hedge Fund Minority
Alloy Ventures Venture Capital Minority
You’re viewing 5 of 34 investors. Get the full list »

ViaCyte Acquisitions (1)

ViaCyte’s most recent deal was a Merger/Acquisition with Janssen (BetaLogics). The deal was made on 18-Dec-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Janssen (BetaLogics) 18-Dec-2015 Merger/Acquisition Biotechnology
To view ViaCyte’s complete acquisitions history, request access »

ViaCyte FAQs

  • When was ViaCyte founded?

    ViaCyte was founded in 1999.

  • Where is ViaCyte headquartered?

    ViaCyte is headquartered in San Diego, CA.

  • What is the size of ViaCyte?

    ViaCyte has 111 total employees.

  • What industry is ViaCyte in?

    ViaCyte’s primary industry is Drug Discovery.

  • Is ViaCyte a private or public company?

    ViaCyte is a Private company.

  • What is the current valuation of ViaCyte?

    The current valuation of ViaCyte is .

  • What is ViaCyte’s current revenue?

    The current revenue for ViaCyte is .

  • How much funding has ViaCyte raised over time?

    ViaCyte has raised $276M.

  • Who are ViaCyte’s investors?

    AMA98 ventures, ARTIS (San Francisco), ATEL Capital Group, Adage Capital Management, and Alloy Ventures are 5 of 34 investors who have invested in ViaCyte.

  • Who are ViaCyte’s competitors?

    Regenerative Medical Solutions, Diamyd Medical, BioCardia, Sernova Biotherapeutics, and Orgenesis are some of the 19 competitors of ViaCyte.

  • When was ViaCyte acquired?

    ViaCyte was acquired on 27-Sep-2022.

  • Who acquired ViaCyte?

    ViaCyte was acquired by Vertex Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process